This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (34) Citing Articles via Google Scholar Google Scholar Articles by Libby, P. Search for Related Content PubMed PubMed Citation Articles by Libby, P.

The Forgotten Majority

Unfinished Business in Cardiovascular Risk Reduction

Donald W. Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.

View larger version (17K): [in a new window]   Figure 1 Percentage of patients experiencing major coronary events, according to several large outcomes studies. AFCAPS/TexCAPS = Air Force Coronary Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; CARE = Cholesterol And Recurrent Events trial; 4S = Scandinavian Simvastatin Survival Study; HPS = Heart Protection Study; LIPID = Long-term Intervention with Pravastatin in Ischemic Disease study; WOS = West of Scotland Coronary Prevention Study. Adapted from Kato H, et al. Am J Epidemiol 1973;97:372–85; HPS Collaborative Group. Lancet 2002;360:7–22; and LaRosa JC, et al. JAMA 1999;282:2340–6.

View larger version (10K): [in a new window]   Figure 2 Cholesterol levels by species. Typical values of plasma low-density lipoprotein cholesterol (LDL-C) in several species, including human. Adapted from Dietschy JM, et al. J Lipid Res 1993;34:1637–59 and Ford ES, et al. Circulation 2003;107:2185–9.

View larger version (24K): [in a new window]   Figure 3 Mean baseline serum cholesterol in the Seven Countries Study. Adapted from Menotti A, et al. Eur J Epidemiol 1993;9:527–36.